Kodiak CFO Sells $1 Million in Stock as Shares Surge 650%. What Investors Should Know
This clinical-stage biotech focused on retinal therapies reported a notable insider sale amid a year of exceptional stock performance.
Overview
John A. Borgeson, the Chief Financial Officer at Kodiak Sciences (NASDAQ:KOD), reported the sale of 30,000 shares through option exercise and immediate disposition on June 4, 2026, according to a SEC Form 4 filing.
Transaction value based on SEC Form 4 weighted average purchase price ($34.10); post-transaction value based on June 4, 2026 market close (price not specified in SEC data).
Details
* 1-year performance calculated using June 4th, 2026 as the reference date.
Source
Originally published at www.fool.com.
Related Articles
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.